Marketing Due Diligence Is Not an Audit. It’s a Stress Test.
When a strategic buyer or PE firm evaluates a multi-site healthcare platform, marketing due diligence follows a consistent logic. It is not a review of creative work. It is not a channel audit. It is a stress test of one specific question: is this marketing function a repeatable, scalable system for generating organic growth – or is it a collection of campaigns that cannot survive a management transition?
Platforms that pass that stress test are rewarded with a premium. Platforms that can’t answer the core questions clearly are treated as having an unproven growth driver. In PE valuation terms, an unproven growth driver is a risk, and risk gets discounted out of the multiple.
The gap between those two outcomes is not a matter of how much healthcare marketing you’ve done. It’s a matter of how well you’ve documented it.
The Four Questions Every Buyer Asks
Across platform sale and recapitalization transactions in multi-site healthcare – behavioral health, ophthalmology, dental, dermatology, urgent care, orthopedics, veterinary, physical therapy, and other specialties – marketing due diligence consistently returns to four questions.
1. Can you connect healthcare marketing spend to patient revenue outcomes?
Attribution infrastructure is the foundation of everything. If you cannot demonstrate a documented, channel-level connection between media investment and production outcomes – at the location level – the marketing story is asserted, not proven. Buyers know the difference. A platform that can show CAC by channel by location over 24 months is telling a fundamentally different story than one that shows blended cost per lead.
One DSO we work with had been running paid search for years with no call tracking, no UTM taxonomy, and no conversion events tied to their scheduling system. Every campaign was optimized for cost per click. When we rebuilt the attribution layer — call tracking, booking confirmations, channel-level CAC by location — cost per booking dropped from $519 to $96, and monthly booking volume grew from 1,099 to 2,842. The numbers didn’t change because the campaigns changed. They changed because, for the first time, the campaigns were optimized against the right signal.
2. Is your patient acquisition cost improving or deteriorating over time?
CAC trend is a signal about marketing efficiency as the platform scales. A declining CAC curve tells buyers that the marketing system is getting smarter – that geographic expansion, media optimization, and process discipline are compounding over time. A flat or rising CAC curve tells the opposite story: that growth is becoming more expensive to sustain, which pressures EBITDA margins at exactly the moment the platform needs to expand.
The CMO who walks into a buyer meeting with a 24-month CAC trend by channel and location is having a fundamentally different conversation than the one who brings a blended portfolio average. One is presenting evidence. The other is presenting a number that can’t be stress-tested.
3. Is same-site growth attributable to marketing, or to external factors?
Buyers distinguish between organic same-site growth and growth that simply reflects a favorable market. Organic growth is repeatable. Market tailwinds are not. When a CMO can demonstrate that same-site revenue improvement – driven by patient reactivation campaigns, service mix optimization, and always-on local market programs – is attributable to a documented marketing system, that growth is underwritten as durable.
A vision care network with multiple brands and over 500 locations had strong top-line growth but couldn’t isolate how much of it came from marketing versus favorable category dynamics and expanded managed care coverage. We rebuilt the attribution model and established a baseline. Over the following period, same-site revenue grew with a 147% multi-channel conversion lift and a $63.24 blended CPA. More importantly, the CMO could now stand in front of the board and explain exactly what drove it.
4. Is the marketing function dependent on key people, or is it documented and transferable?
This is the question that catches the most platforms off guard. A marketing function that performs because of the CMO’s judgment, relationships, and institutional knowledge is a key-person risk. Under new ownership, that risk is a liability. A marketing function built on documented systems, standardized processes, and attribution infrastructure that any competent team can operate is a different kind of asset entirely.
This question has become standard in healthcare platform transactions over the last several years, and the bar keeps moving. PE firms that have been through multiple healthcare platform cycles now ask it early — not as a formality, but because they’ve seen what happens to marketing performance when a strong CMO exits and the infrastructure wasn’t built to outlast them.
What “Exit-Ready” Marketing Infrastructure Actually Looks Like
Exit-ready marketing is not a marketing audit you commission six months before a transaction. It is the infrastructure you build – and the data you accumulate – over the course of the hold period.
At the infrastructure level, that means attribution systems connecting every media dollar to production outcomes at the location level — not blended portfolio averages. It means CAC trend data with channel-level and location-level detail over multiple years, so the efficiency curve is visible and defensible. It means same-site revenue contribution from marketing that is documented separately from acquisition growth, so organic performance can be evaluated on its own terms. And it means de novo ramp data showing that new locations hit modeled EBITDA contribution on timeline — not just that they eventually got there.
Underlying all of it: documented processes. Written playbooks, standardized campaign architectures, and reporting frameworks that any competent team can operate. This is what makes the system transferable rather than person-dependent — and what gives buyers confidence that the performance they’re underwriting will hold after the transaction closes.
Building this takes 18 to 24 months of consistent execution. CMOs who begin when the transaction timeline becomes clear are almost always too late to build the evidence base. The time to build exit-ready marketing infrastructure is at the beginning of the hold period, not the end.
Why Healthcare EBITDA Quality Is the Real Argument
The most sophisticated version of this argument goes beyond whether healthcare marketing survives marketing due diligence scrutiny. It goes to the quality of the EBITDA that marketing has generated.
Not all EBITDA is priced equally in multi-site healthcare transactions. EBITDA driven by acquisitions requires continued capital deployment to sustain. EBITDA driven by organic same-site growth from a documented, repeatable marketing system does not. Buyers pay a higher multiple for the latter because it is more durable, more scalable, and less dependent on continued M&A activity.
When a CMO can walk into a marketing due diligence process and demonstrate that a material portion of the platform’s EBITDA growth is attributable to a marketing system — not market timing, not one-time operational improvements, not acquisitions — the conversation at the valuation table changes. The multiple applied to that EBITDA reflects its quality, not just its quantity.
Most PE sponsors already understand this intuitively. What they’re looking for in due diligence is the evidence that proves it — the attribution data, the trend lines, the documented system. The CMO’s job is to have built that evidence before the process starts.
The Marketing Story in the Investment Memorandum
The investment memorandum prepared for a platform sale or recap tells the marketing story in financial terms. It shows CAC trend over three to five years. It shows same-site revenue growth attributable to marketing initiatives. It shows de novo ramp performance versus the investment thesis model. And it shows the attribution infrastructure that makes all of those numbers real rather than asserted.
That section of the investment memorandum is increasingly scrutinized by sophisticated buyers. They understand that a platform’s marketing capability is a meaningful determinant of its post-acquisition performance. They want to know that what worked under the current ownership group will continue to work under the next one.
CMOs who have built the infrastructure, documented the process, and accumulated the trend data have a story to tell. CMOs who have not are asking buyers to take a position on a marketing function they cannot underwrite.
“Your next recap or platform sale will require a marketing story. The time to build it is now – while there is runway to prove the model.”
Every Agency Creative engagement starts with a diagnostic — a structured audit of your current marketing infrastructure against the four questions above. We map what exists, what’s missing, and what would fail under buyer scrutiny. From there we build what’s needed: attribution infrastructure, CAC reporting by channel and location, same-site growth documentation, and the board-ready financial narrative that connects all of it.
If you’re 18 months from a transaction, we can tell you what can still be built in time. If you’re at the beginning of a hold period, we can build the full model from the ground up. Either way, the conversation starts at agencycreative.com.
Learn how Agency Creative can help boost your brand by calling us at 972.488.1660 or by contacting us online.
See More Work
